JP2022518929A5 - - Google Patents

Info

Publication number
JP2022518929A5
JP2022518929A5 JP2021544144A JP2021544144A JP2022518929A5 JP 2022518929 A5 JP2022518929 A5 JP 2022518929A5 JP 2021544144 A JP2021544144 A JP 2021544144A JP 2021544144 A JP2021544144 A JP 2021544144A JP 2022518929 A5 JP2022518929 A5 JP 2022518929A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
modified
acid bases
equal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544144A
Other languages
English (en)
Japanese (ja)
Other versions
JP7557469B2 (ja
JP2022518929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015701 external-priority patent/WO2020160163A1/en
Publication of JP2022518929A publication Critical patent/JP2022518929A/ja
Publication of JP2022518929A5 publication Critical patent/JP2022518929A5/ja
Priority to JP2024158813A priority Critical patent/JP2025000693A/ja
Application granted granted Critical
Publication of JP7557469B2 publication Critical patent/JP7557469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544144A 2019-01-29 2020-01-29 Appの発現を低減するための化合物及び方法 Active JP7557469B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158813A JP2025000693A (ja) 2019-01-29 2024-09-13 Appの発現を低減するための化合物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962798353P 2019-01-29 2019-01-29
US62/798,353 2019-01-29
US201962841169P 2019-04-30 2019-04-30
US62/841,169 2019-04-30
US201962915764P 2019-10-16 2019-10-16
US62/915,764 2019-10-16
PCT/US2020/015701 WO2020160163A1 (en) 2019-01-29 2020-01-29 Compounds and methods for reducing app expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158813A Division JP2025000693A (ja) 2019-01-29 2024-09-13 Appの発現を低減するための化合物及び方法

Publications (3)

Publication Number Publication Date
JP2022518929A JP2022518929A (ja) 2022-03-17
JP2022518929A5 true JP2022518929A5 (cg-RX-API-DMAC7.html) 2023-02-02
JP7557469B2 JP7557469B2 (ja) 2024-09-27

Family

ID=71840111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544144A Active JP7557469B2 (ja) 2019-01-29 2020-01-29 Appの発現を低減するための化合物及び方法
JP2024158813A Pending JP2025000693A (ja) 2019-01-29 2024-09-13 Appの発現を低減するための化合物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158813A Pending JP2025000693A (ja) 2019-01-29 2024-09-13 Appの発現を低減するための化合物及び方法

Country Status (6)

Country Link
US (1) US20220380773A1 (cg-RX-API-DMAC7.html)
EP (1) EP3918073A4 (cg-RX-API-DMAC7.html)
JP (2) JP7557469B2 (cg-RX-API-DMAC7.html)
TW (1) TW202043472A (cg-RX-API-DMAC7.html)
UY (1) UY38562A (cg-RX-API-DMAC7.html)
WO (1) WO2020160163A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY203356A (en) 2018-01-12 2024-06-25 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019140236A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019169243A1 (en) 2018-03-02 2019-09-06 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
AU2019405783B2 (en) * 2018-12-19 2026-03-26 Alnylam Pharmaceuticals, Inc. Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
JP7725370B2 (ja) * 2019-04-03 2025-08-19 ブリストル-マイヤーズ スクイブ カンパニー Angptl2アンチセンスオリゴヌクレオチドおよびその使用
KR20220062517A (ko) 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 결합 변형된 올리고머 화합물 및 이의 용도
MX2023001222A (es) 2020-07-28 2023-04-26 Ionis Pharmaceuticals Inc Compuestos y metodos para reducir la expresion de app.
WO2022165172A1 (en) * 2021-01-29 2022-08-04 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing amyloid precursor protein (app)
EP4416284A1 (en) * 2021-10-15 2024-08-21 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2025045195A1 (zh) * 2023-08-31 2025-03-06 上海拓界生物医药科技有限公司 靶向APP的RNAi剂及其医药用途
WO2025228429A1 (zh) * 2024-04-30 2025-11-06 北京安龙生物医药有限公司 靶向淀粉样前体蛋白基因的寡核苷酸及其用途
WO2025261396A1 (zh) * 2024-06-18 2025-12-26 艾码生物科技(南京)有限公司 靶向app的rna干扰方法、核酸及其应用
WO2026092658A2 (en) * 2024-10-31 2026-05-07 Sanegene Bio Usa Inc. Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511387A (ja) * 1991-12-24 1994-12-22 アイシス・ファーマシューティカルス・インコーポレーテッド β−アミロイド調節のための組成物および方法
US20030232435A1 (en) * 2002-06-14 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of amyloid beta protein precursor expression
CA2528963A1 (en) * 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
GB0324854D0 (en) * 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
US20110166197A1 (en) 2008-02-19 2011-07-07 Edunn Biotechnology, Inc. Antisense Modulation Of Amyloid Beta Protein Expression
US20100190807A1 (en) * 2008-08-26 2010-07-29 Senex Biotechnology, Inc. CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
WO2011130742A2 (en) * 2010-04-16 2011-10-20 Wisconsin Alumni Research Foundation Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
KR20160027968A (ko) 2013-06-07 2016-03-10 라나 테라퓨틱스, 인크. Foxp3 발현을 조절하기 위한 조성물 및 방법
JP2016531570A (ja) 2013-08-16 2016-10-13 ラナ セラピューティクス インコーポレイテッド ユークロマチン領域を標的とするオリゴヌクレオチド
MY192689A (en) 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US9926556B2 (en) 2014-04-28 2018-03-27 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
WO2019169243A1 (en) * 2018-03-02 2019-09-06 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein

Similar Documents

Publication Publication Date Title
JP7354342B2 (ja) タウ発現を調節するための組成物
JP2021530204A5 (cg-RX-API-DMAC7.html)
JP6622214B2 (ja) Sod−1発現を調節するための組成物
JP6126009B2 (ja) α−シヌクレイン発現の調節
AU2019384181B2 (en) Compounds and methods for reducing prion expression
JP2022515193A5 (cg-RX-API-DMAC7.html)
JP2022520986A5 (cg-RX-API-DMAC7.html)
JP2023536472A5 (cg-RX-API-DMAC7.html)
JP2021502095A5 (cg-RX-API-DMAC7.html)
TW201831686A (zh) α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
JP2025000693A (ja) Appの発現を低減するための化合物及び方法
JP2021522800A5 (cg-RX-API-DMAC7.html)
JP7446443B2 (ja) Smn2を調節するための化合物及び方法
MX2015003841A (es) Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica.
JP2022509625A5 (cg-RX-API-DMAC7.html)
JP2022533358A5 (cg-RX-API-DMAC7.html)
JP2023543215A5 (cg-RX-API-DMAC7.html)
JP2023528755A5 (cg-RX-API-DMAC7.html)
JP2023536472A (ja) Appの発現を低減するための化合物及び方法
JP2023536994A5 (cg-RX-API-DMAC7.html)
CN118451183A (zh) 用于调节scn1a表达的化合物和方法
JP2018525015A (ja) 脊髄性筋萎縮症におけるエクソン包含のための修飾アンチセンスオリゴマー
JP2022515140A5 (cg-RX-API-DMAC7.html)
JP2022534086A5 (cg-RX-API-DMAC7.html)
JP2022500079A5 (cg-RX-API-DMAC7.html)